Mississippi Attorney General Jim Hood said he hopes that lawmakers will use $20.2 million that the state received from settling its lawsuit against pharmaceutical companies to fund mental health programs next year.
Generic drug developer Mylan Inc. said that Standard & Poor's Ratings Services upgraded the company's corporate credit ratings, citing its use of cash flow to cut its debt load.
Vertex Pharmaceuticals Inc. said that VX-765 met key safety and tolerability goals in a midstage study. The six-week trial included 60 people with treatment-resistant epilepsy, a type of epilepsy where seizures start and occur in a specific part of the brain.
Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said a monthly version of the diabetes treatment Byetta performed positively in a small, mid-stage study that measured its effectiveness, safety and tolerability.
Federal officials said that the consumer health unit of Johnson & Johnson will be barred from resuming operations at a Pennsylvania manufacturing plant linked to millions of bottles of defective medicines until it meets quality standards.
The Tharo PA2000 Specialty Tamp Label Printer/Applicator requires minimal adjustments and has a quick setup and changeover for applying labels to the top or side of varying height products.
IDBS will provide an enterprise translational medicine platform for the Integrated Cancer Centre at King’s Health Partners to develop targeted, personalized, cancer therapies.
Grace Davison Discovery Sciences announced the opening of a new technical service Knowledge Centre in Southern India for customers in the pharmaceutical and biotechnology industries.
Epizyme, Inc. announced a worldwide partnership with Eisai Co., Ltd., Tokyo, Japan to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients.
A study assessing a new longer-acting form of insulin—degludec— has shown that patients could achieve the same level of glucose control when the insulin was administered just three times a week instead of daily.
Relapse remains a leading cause of death from childhood acute lymphoblastic leukemia and newly identified mutations in a gene named CREBBP may be helping the cancer resist steroid treatment and fueling ALL's return.
Australian drug development company Biotron Limited has completed stage one of a landmark human trial of its lead Hepatitis C drug candidate, BIT225.
Genentech announced that two-year results from a pivotal Phase 3 trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.
In the fall of 1917, a new strain of influenza swirled around the globe. At first, it resembled a typical flu epidemic. However, in the summer of 1918, a deadlier version of the same virus began spreading, killing 50 million people.
Researchers have identified a chemical compound that may eventually lead to a drug that fights cancers that are dependent on a particular anti-viral enzyme for growth.